

# Resource Summary Report

Generated by [dkNET](#) on Jul 31, 2026

## CD 8, T-cell surface glycoprotein

RRID:AB\_2335985

Type: Antibody

---

### Proper Citation

Ventana Medical Systems Cat# 790-4460, RRID:AB\_2335985

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2335985](http://antibodyregistry.org/AB_2335985)

**Proper Citation:** Ventana Medical Systems Cat# 790-4460, RRID:AB\_2335985

**Target Antigen:** CD8

**Host Organism:** rabbit

**Clonality:** monoclonal

**Comments:** Used By NYUIHC-1073

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

**Antibody Name:** CD 8, T-cell surface glycoprotein

**Description:** This monoclonal targets CD8

**Clone ID:** SP57

**Antibody ID:** AB\_2335985

**Vendor:** Ventana Medical Systems

**Catalog Number:** 790-4460

**Alternative Catalog Numbers:** 05937248001

**Record Creation Time:** 20250820T045450+0000

**Record Last Update:** 20250820T201659+0000

---

### Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for CD 8, T-cell surface glycoprotein.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 28 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Sacco JJ, et al. (2025) Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific. Cell reports. Medicine, 6(4), 102076.

Ren W, et al. (2025) Whole-genome sequencing reveals three follicular lymphoma subtypes with distinct cell of origin and patient outcomes. Cell reports. Medicine, 6(8), 102278.

Lee YJ, et al. (2025) Tumor-specific but immunosuppressive CD39+CD8+ T cells exhibit double-faceted roles in clear cell renal cell carcinoma. Cell reports. Medicine, 102360.

Urai S, et al. (2025) Challenges in diagnosing paraneoplastic isolated adrenocorticotrophic hormone deficiency: Insights from cancer histology and human leukocyte antigen analysis. Journal of neuroendocrinology, e70074.

Digomann D, et al. (2025) Soluble TIM-3 and galectin-9 predict survival in gastric and gastroesophageal junction cancer. iScience, 28(11), 113871.

Hockemeyer K, et al. (2024) The stress response regulator HSF1 modulates natural killer cell anti-tumour immunity. Nature cell biology, 26(10), 1734.

Urai S, et al. (2024) The early-stage clinical course of anti-pituitary-specific transcription factor-1 hypophysitis diagnosed post-immune checkpoint inhibitor treatment: A case with review of literature. Journal of neuroendocrinology, 36(6), e13395.

Sun Y, et al. (2024) Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma. Cancer cell, 42(1), 135.

Li Y, et al. (2024) Multimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancer. Cell reports. Medicine, 5(2), 101397.

Donati B, et al. (2024) Spatial Distribution of Immune Cells Drives Resistance to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. *Cancer immunology research*, 12(1), 120.

Kanzawa M, et al. (2024) Effects of the Cortisol Milieu on Tumor-Infiltrating Immune Cells in Corticotroph Tumors. *Endocrinology*, 165(4).

Tabata M, et al. (2023) Inter- and intra-tumor heterogeneity of genetic and immune profiles in inherited renal cell carcinoma. *Cell reports*, 42(7), 112736.

Chiu D, et al. (2023) A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma. *Cancer research communications*, 3(1), 130.

van Hijfte L, et al. (2023) Alternative normalization and analysis pipeline to address systematic bias in NanoString GeoMx Digital Spatial Profiling data. *iScience*, 26(1), 105760.

Park JA, et al. (2023) Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody. *Journal for immunotherapy of cancer*, 11(3).

Basolo A, et al. (2023) Autopsy Study of Testicles in COVID-19: Upregulation of Immune-Related Genes and Downregulation of Testis-Specific Genes. *The Journal of clinical endocrinology and metabolism*, 108(4), 950.

Urai S, et al. (2023) Paraneoplastic isolated adrenocorticotrophic hormone deficiency revealed after immune checkpoint inhibitors therapy: new insights into anti-corticotroph antibody. *Frontiers in immunology*, 14, 1284301.

Shim J, et al. (2022) Integrated Analysis of Single-Cell and Spatial Transcriptomics in Keloids: Highlights on Fibrovascular Interactions in Keloid Pathogenesis. *The Journal of investigative dermatology*, 142(8), 2128.

Golesworthy B, et al. (2022) Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. *Frontiers in oncology*, 12, 860767.

Poma AM, et al. (2022) Suppression of Pituitary Hormone Genes in Subjects Who Died From COVID-19 Independently of Virus Detection in the Gland. *The Journal of clinical endocrinology and metabolism*, 107(8), 2243.